Page 1

Pharma Mar • PharmaMar Group reports 9 month 2021 financial results The Group's recurring revenues ( sales plus royalties ) grew by 31 % to € 119 million during the first 9 months . • Total revenues amounted to € 144 million . • • The Group recorded a net profit of € 54.7 million for the first 9 months . Strong operating cash flow generation with € 25 million over the first 9 months despite intensification of R & D investments . Madrid , October 28th , 2021. -PharmaMar Group ( MSE : PHM ) reported that recurring revenues , comprising net sales plus royalties received from sales by our partners , increased by 31 % year - on - year to € 119 million for the first 9 months of the year . As in previous quarters , the increase in recurring revenues was mainly driven by the good performance of our oncology business unit . Oncology sales revenues reached € 88.7 million year - to - date in 2021 , an increase of 21 % compared with the same period last year . It is worth highlighting the growth in revenues from Zepzelca® ( lurbinectedin ) in Europe under the compassionate use authorization program , which amounted to € 23.3 million through September 30th . This represents an increase of 77.7 % when compared with the same period last year . Yondelis® ( trabectedin ) sales remained stable in 9M 2021 , € 56.5 million compared to € 57.1 million in 9M 2020 . Royalty revenues amounted to € 27.2 million in 9M 2021 , compared to € 7.4 million over the same period in 2020. This significant increase was mainly driven by royalties received from our partner Jazz Pharmaceuticals , which accounted for € 25.2 million and have been entirely generated as a result of sales of lurbinectedin in the US . As our partner Jazz Pharmaceuticals has not reported its 3Q 2021 results yet , our recorded 3Q 2021 royalties are an estimate based on our conservative , best available information . 1